Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, UCLA, Los Angeles, California
Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, UCLA, Los Angeles, California.
J Nucl Med. 2019 Sep;60(Suppl 2):3S-12S. doi: 10.2967/jnumed.118.220558.
In this article, we provide an overview of established and emerging conventional nuclear medicine and PET imaging biomarkers, as the diagnostic nuclear medicine portfolio is rapidly expanding. Next, we review briefly nuclear theranostic approaches that have already entered or are about to enter clinical routine. Using some approximations and taking into account emerging applications, we also provide some simplified business forecasts for nuclear theranostics. We argue that an optimistic outlook by the nuclear medicine community is crucial to the growth of the specialty and emphasize the urgent need for training adaptations.
在本文中,我们提供了已建立和新兴的常规核医学和 PET 成像生物标志物的概述,因为诊断核医学产品组合正在迅速扩展。接下来,我们简要回顾了已经进入或即将进入临床常规的核治疗方法。使用一些近似值并考虑到新兴的应用,我们还为核治疗提供了一些简化的业务预测。我们认为,核医学界的乐观前景对该专业的发展至关重要,并强调了培训调整的迫切需要。